PortalPublikationenNail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA)...

Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes

Standard

Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. / Augustin, M; Blome, C; Costanzo, A; Dauden, E; Ferrandiz, C; Girolomoni, G; Gniadecki, R; Iversen, L; Menter, A; Michaelis-Wittern, K; Morita, A; Nakagawa, H; Reich, K.

in: BRIT J DERMATOL, Jahrgang 170, Nr. 3, 01.03.2014, S. 591-8.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Augustin, M, Blome, C, Costanzo, A, Dauden, E, Ferrandiz, C, Girolomoni, G, Gniadecki, R, Iversen, L, Menter, A, Michaelis-Wittern, K, Morita, A, Nakagawa, H & Reich, K 2014, 'Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes', BRIT J DERMATOL, Jg. 170, Nr. 3, S. 591-8. https://doi.org/10.1111/bjd.12664

APA

Augustin, M., Blome, C., Costanzo, A., Dauden, E., Ferrandiz, C., Girolomoni, G., Gniadecki, R., Iversen, L., Menter, A., Michaelis-Wittern, K., Morita, A., Nakagawa, H., & Reich, K. (2014). Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. BRIT J DERMATOL, 170(3), 591-8. https://doi.org/10.1111/bjd.12664

Vancouver

Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. BRIT J DERMATOL. 2014 Mär 1;170(3):591-8. https://doi.org/10.1111/bjd.12664

Bibtex

@article{a84ebb52472341f0a064a6d2cf2768ed,
title = "Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes",
abstract = "BACKGROUND: Existing tools for nail psoriasis are complex and may not adequately measure outcomes that are important to patients.OBJECTIVES: We have developed and validated a new tool, the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA), with three components: a questionnaire assessing quality of life (NAPPA-QoL), a two-part questionnaire assessing patient-relevant treatment benefits (the Patient Benefit Index, NAPPA-PBI) and a psoriasis Clinical Assessment of Severity (NAPPA-CLIN).METHODS: Development of the questionnaires involved multiple steps: (i) collection of items about nail psoriasis-related impairments and treatment goals; (ii) selection of 48 items by an expert panel, including patients; (iii) translation into eight languages; (iv) feasibility testing and (v) longitudinal validation in six countries.RESULTS: Patients found the questionnaires clear (84%) and comprehensible (95%). NAPPA-QoL and NAPPA-PBI scores correlated moderately with clinical outcomes [e.g. Nail Psoriasis Severity Index (NAPSI)] and markedly with other quality-of-life questionnaires (e.g. EQ-5D{\texttrademark}). Both questionnaires were sensitive to change. Internal consistency was good (Cronbach α ≥ 0.88 for all scales). The NAPPA-CLIN, a brief version of NAPSI that involves assessment of only four digits rather than all 20, was found to correlate highly with total NAPSI score (r = 0.97, P < 0.001).CONCLUSIONS: Overall, the three-component NAPPA tool is a valid, reliable and practical instrument to assess patient-relevant nail psoriasis outcomes.",
keywords = "Adult, Aged, Aged, 80 and over, Arthritis, Psoriatic, Feasibility Studies, Female, Humans, Male, Middle Aged, Nail Diseases, Patient Outcome Assessment, Patient Satisfaction, Psoriasis, Quality of Life, Treatment Outcome, Young Adult",
author = "M Augustin and C Blome and A Costanzo and E Dauden and C Ferrandiz and G Girolomoni and R Gniadecki and L Iversen and A Menter and K Michaelis-Wittern and A Morita and H Nakagawa and K Reich",
note = "{\textcopyright} 2013 British Association of Dermatologists.",
year = "2014",
month = mar,
day = "1",
doi = "10.1111/bjd.12664",
language = "English",
volume = "170",
pages = "591--8",
journal = "BRIT J DERMATOL",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes

AU - Augustin, M

AU - Blome, C

AU - Costanzo, A

AU - Dauden, E

AU - Ferrandiz, C

AU - Girolomoni, G

AU - Gniadecki, R

AU - Iversen, L

AU - Menter, A

AU - Michaelis-Wittern, K

AU - Morita, A

AU - Nakagawa, H

AU - Reich, K

N1 - © 2013 British Association of Dermatologists.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - BACKGROUND: Existing tools for nail psoriasis are complex and may not adequately measure outcomes that are important to patients.OBJECTIVES: We have developed and validated a new tool, the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA), with three components: a questionnaire assessing quality of life (NAPPA-QoL), a two-part questionnaire assessing patient-relevant treatment benefits (the Patient Benefit Index, NAPPA-PBI) and a psoriasis Clinical Assessment of Severity (NAPPA-CLIN).METHODS: Development of the questionnaires involved multiple steps: (i) collection of items about nail psoriasis-related impairments and treatment goals; (ii) selection of 48 items by an expert panel, including patients; (iii) translation into eight languages; (iv) feasibility testing and (v) longitudinal validation in six countries.RESULTS: Patients found the questionnaires clear (84%) and comprehensible (95%). NAPPA-QoL and NAPPA-PBI scores correlated moderately with clinical outcomes [e.g. Nail Psoriasis Severity Index (NAPSI)] and markedly with other quality-of-life questionnaires (e.g. EQ-5D™). Both questionnaires were sensitive to change. Internal consistency was good (Cronbach α ≥ 0.88 for all scales). The NAPPA-CLIN, a brief version of NAPSI that involves assessment of only four digits rather than all 20, was found to correlate highly with total NAPSI score (r = 0.97, P < 0.001).CONCLUSIONS: Overall, the three-component NAPPA tool is a valid, reliable and practical instrument to assess patient-relevant nail psoriasis outcomes.

AB - BACKGROUND: Existing tools for nail psoriasis are complex and may not adequately measure outcomes that are important to patients.OBJECTIVES: We have developed and validated a new tool, the Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA), with three components: a questionnaire assessing quality of life (NAPPA-QoL), a two-part questionnaire assessing patient-relevant treatment benefits (the Patient Benefit Index, NAPPA-PBI) and a psoriasis Clinical Assessment of Severity (NAPPA-CLIN).METHODS: Development of the questionnaires involved multiple steps: (i) collection of items about nail psoriasis-related impairments and treatment goals; (ii) selection of 48 items by an expert panel, including patients; (iii) translation into eight languages; (iv) feasibility testing and (v) longitudinal validation in six countries.RESULTS: Patients found the questionnaires clear (84%) and comprehensible (95%). NAPPA-QoL and NAPPA-PBI scores correlated moderately with clinical outcomes [e.g. Nail Psoriasis Severity Index (NAPSI)] and markedly with other quality-of-life questionnaires (e.g. EQ-5D™). Both questionnaires were sensitive to change. Internal consistency was good (Cronbach α ≥ 0.88 for all scales). The NAPPA-CLIN, a brief version of NAPSI that involves assessment of only four digits rather than all 20, was found to correlate highly with total NAPSI score (r = 0.97, P < 0.001).CONCLUSIONS: Overall, the three-component NAPPA tool is a valid, reliable and practical instrument to assess patient-relevant nail psoriasis outcomes.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Arthritis, Psoriatic

KW - Feasibility Studies

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Nail Diseases

KW - Patient Outcome Assessment

KW - Patient Satisfaction

KW - Psoriasis

KW - Quality of Life

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1111/bjd.12664

DO - 10.1111/bjd.12664

M3 - SCORING: Journal article

C2 - 24117393

VL - 170

SP - 591

EP - 598

JO - BRIT J DERMATOL

JF - BRIT J DERMATOL

SN - 0007-0963

IS - 3

ER -